Status:

RECRUITING

68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)

Lead Sponsor:

Institut Curie

Conditions:

Triple Negative Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patien...

Detailed Description

Prospective multicenter study evaluating the prediction of histological response of pembrolizumab in combination with neoadjuvant chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients ...

Eligibility Criteria

Inclusion

  • Female with age ≥ 18 years,
  • Patients with previously untreated, non-metastatic, centrally confirmed TNBC for whom a neoadjuvant treatment with chemotherapy + pembrolizumab is the recommended option as standard of care,
  • Patients with measurable targets according to RECIST/PERCIST criteria,
  • Patients without distant metastasis based on staging 18F-FDG PET/CT,
  • Patients with tumor tissue available,
  • Patients who provided a signed written informed consent,
  • Patient ability to comply with protocol requirements,
  • Patients covered by a health insurance system.

Exclusion

  • Pregnant and lactating women,
  • Patients with prior anti-PD(L)1 immunotherapy,
  • Patients with any contra-indication to chemo-immunotherapy standard of care therapy, per investigator assessment,
  • Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent,
  • Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons,
  • Person deprived of liberty or under guardianship

Key Trial Info

Start Date :

October 14 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2032

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06349512

Start Date

October 14 2024

End Date

November 30 2032

Last Update

December 22 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Hôpital Privé d'Antony

Antony, France, 92160

2

Institut Curie -site Paris

Paris, France, 75005

3

GH Diaconesses Croix Saint-Simon

Paris, France, 75020

4

Institut Curie -site St Cloud

Saint-Cloud, France, 92210

68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) | DecenTrialz